Study details
Enrolling now
Psilocybin on Brain Mechanisms of Motivation in OUD
Anna Rose Childress, Ph.D.
NCT IDNCT06810310ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
24
Study length
about 4 months
Ages
18–60
Locations
1 site in PA
About this study
This trial is testing whether psilocybin affects brain circuits related to motivation and addiction in people with opioid use disorder. Participants will receive either a low or high dose of psilocybin, followed by assessments using fMRI to examine brain activity before and after treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Psilocybin (high dose)
- 2.Take psilocybin (low dose)
PhasePhase 2
DrugPsilocybin (high dose)
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
oral
Body systems
Psychiatry / Mental Health